Salvage, dose intense and high-dose chemotherapy for the treatment of poor prognosis or recurrent germ cell tumours

Cancer Treatment Reviews

Volumn 31, Issue 3, 2005, Pages 197-209

  El Helw, L ^a   Coleman, R E ^a  

^a WESTON PARK HOSPITAL   (United Kingdom)

Author keywords

Autologous stem cell; Bone marrow transplantation; Germ cell tumours; High dose chemotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; ETOPOSIDE; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; MESNA; OXALIPLATIN; PACLITAXEL; THIOTEPA; VINBLASTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADVANCED CANCER; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG FATALITY; DRUG MEGADOSE; ENTEROCOLITIS; FEBRILE NEUTROPENIA; GERM CELL TUMOR; GRANULOCYTOPENIA; HEARING IMPAIRMENT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; KIDNEY DISEASE; LEUKOPENIA; MALE; METASTASIS; MUCOSA INFLAMMATION; NAUSEA; NEPHROTOXICITY; NEUROMUSCULAR DISEASE; NEUROTOXICITY; PERIPHERAL NEUROPATHY; PROGNOSIS; RECURRENT CANCER; SALVAGE THERAPY; SEPSIS; THROMBOCYTOPENIA; TREATMENT FAILURE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; GERMINOMA; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IFOSFAMIDE; ORGANOPLATINUM COMPOUNDS; PACLITAXEL; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS; SALVAGE THERAPY;

EID: 20344396588     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ctrv.2005.02.001     Document Type: Article

References (54)

1. T. Aareleid M. Sant G. Hédelin Improved survival for patients with testicular cancer in Europe since 1978. Eurocare Working Group Eur J Cancer 34 14 1998 2236-2240
2. E.J. Feuer C.M. Frey O.W. Brawley et al. After a treatment breakthrough:a comparison of trial and population-based data for advanced testicular cancer J Clin Oncol 12 2 1994 368-377
3. G.J. Bosel R.J. Motzer Testicular germ-cell cancer N Engl J Med 337 4 1997 242-253
4. International Germ Cell Consensus Classification: A prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol 1997;15(2):594-603
5. D.J. Sonneveld H.J. Hoekstra W.T. van der Graaf et al. Improved long term survival of patients with metastatic nonseminomatous testicular germ cell carcinoma in relation to prognostic classification systems during the cisplatin era Cancer 191 7 2001 1304-1315
6. A. Horwich M. Mason W. Hendry Testicular tumours 2nd ed. In: R. Souhami I. Tannock P. Hohenberger J.C. Horiot editors Oxford textbook of oncology vol. 2 2002 Oxford University Press New York 2007-2033
7. S.D. Williams R. Birch L.H. Einhorn et al. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide N Engl J Med 316 23 1987 1435-1440
8. P.J. Loehrer Sr. R. Gonin C.R. Nichols et al. Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumour J Clin Oncol 16 7 1998 2500-2504
9. J.A. McCaffrey M. Mazumdar D.F. Bajorin et al. Ifosfamide- and cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumors: Response and survival J Clin Oncol 15 7 1997 2559-2563
10. A. Harstrick H.J. Schmoll H. Wilke et al. Cisplatin, etoposide, and ifosfamide salvage therapy for refractory or relapsing germ cell carcinoma J Clin Oncol 9 9 1991 1549-1555
11. M. Ghosn J.P. Droz C. Theodore et al. Salvage chemotherapy in refractory germ cell tumors with etoposide (VP-16) plus ifosfamide plus high-dose cisplatin. A VIhP regimen Cancer 162 1 1988 24-27
12. C. Bokemeyer J.T. Hartmann M.A. Kuczyk et al. Recent strategies for the use of paclitaxel in the treatment of urological malignancies World J Urol 16 2 1998 155-162
13. C. Bokemeyer J. Beyer B. Metzner et al. Phase II study of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer Ann Oncol 7 1 1996 31-34
14. R.J. Motzer J. Sheinfeld M. Mazumdar et al. Paclitaxel, ifosfamide and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer J Clin Oncol 18 12 2000 2413-2418
15. K. Kawai J. Miyazaki S. Tsukamoto et al. Paclitaxel, ifosfamide and cisplatin regimen is feasible for Japanese patients with advanced germ cell cancer Jpn J Clin Oncol 33 3 2003 127-131
16. C. Bokemeyer A. Gerl P. Schoffski et al. Gemcitabine in patients with relapsed or cisplatin-refractory testicular cancer J Clin Oncol 17 2 1999 512-516
17. L.H. Einhorn M.J. Stender S.D. William Phase II trial of gemcitabine in refractory germ cell tumors J Clin Oncol 17 2 1999 509-511
18. S. Hinton P. Catalano L. Einhorn et al. Phase II study of paclitaxel plus gemcitabine in refractory germ cell tumors (E9897): A trial of the Eastern Cooperative Oncology Group J Clin Oncol 20 7 2002 1859-1863
19. C. Kollmannsberger O. Rick H.G. Derigs et al. Activity of oxaliplatin in patients with relapsed or cisplatin-refractory germ cell cancer: A study of the German Testicular Cancer Study Group J Clin Oncol 20 8 2002 2031-2037
20. C. Kollmannsberger J. Beyer R. Liersch et al. Combination chemotherapy with gemcitabine plus oxaliplatin in patients with intensively pretreated or refractory germ cell cancer: A study of the German Testicular Cancer Study Group J Clin Oncol 122 1 2004 108-114
21. D. Pectasides M. Pectasides D. Farmakis et al. Gemcitabine and oxaliplatin (GEMOX) in patients with cisplatin-refractory germ cell tumors: A phase II study Ann Oncol 15 3 2004 493-497
22. W.D. DeWys C. Begg R. Slayton et al. Chemotherapy for advanced germinal cell neoplasms: Preliminary report of an Eastern Cooperative Oncology Group Study Cancer Treat Rep 63 9-10 1979 1675-1680
23. M.K. Samson S.E. Rivkin S.E. Jones et al. Dose-response and dose-survival advantage for high versus low-dose cisplatin combined with vinblastine and bleomycin in disseminated testicular cancer. A Southern Oncology Group Study Cancer 3 3 1984 1029-1035
24. R.F. Ozols D.C. Ihde W.M. Linehan et al. A randomised trial of standard chemotherapy vs a high-dose chemotherapy regimen in the treatment of poor prognosis nonseminatous germ-cell tumors J Clin Oncol 6 6 1988 1031-1040
25. C.R. Nichols S.D. William P.J. Loehrer et al. Randomised study of cisplatin dose intensity in poor-risk germ cell tumours: A South-eastern Cancer study group and Southwest Oncology Group protocol J Clin Oncol 9 7 1991 1163-1172
26. C. Bokemeyer A. Harstrick J. Beyer et al. The use of dose-intensified chemotherapy in the treatment of metastatic nonseminomatous testicular germ-cell tumors Semin Oncol 25 2 Suppl. 4 1998 24-32
27. J.N. Wettlaufer A.S. Feiner W.A. Robinson Vincristine, cisplatin and bleomycin with surgery in the management of advanced metastatic non-seminatous testis tumors Cancer 53 2 1984 203-209
28. A. Horwich M. Brada J. Nicholls et al. Intensive induction chemotherapy for poor-risk non-seminomatous germ-cell tumours Eur J Cancer Clin Oncol 25 2 1989 177-184
29. A. Horwich D.P. Dearnaley A. Norman et al. Accelerated chemotherapy for poor prognosis germ-cell tumours Eur J Cancer 30A 11 1994 1606-1611
30. S.B. Kaye G.M. Mead S. Fossa et al. Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: A Randomized Medical Research Council/European Organization for Research and Treatment of Cancer study J Clin Oncol 16 2 1998 692-701
31. C.R. Nichols G. Tricot S.D. Williams et al. Dose-intensive chemotherapy in refractory germ cell cancer - a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation J Clin Oncol 7 7 1989 932-939
32. J.P. Droz J.L. Pico M. Ghosn et al. Long term survivors after salvage high dose chemotherapy with bone marrow rescue in refractory Germ cell cancer Eur J Cancer 27 7 1991 831-835
33. E.R. Broun C.R. Nichols L.H. Einhorn G.J. Tricot Salvage therapy with high-dose chemotherapy and autologous bone marrow support in the treatment of primary non-seminomatous mediastinal germ cell tumours Cancer 68 7 1991 1513-1515
34. E.R. Broun C.R. Nichols G. Tricot et al. High-dose carboplatin/VP-16 plus ifosfamide with autologous bone marrow support in the treatment of refractory germ cell tumours Bone Marrow Transpl 7 1 1991 53-56
35. G. Rosti L. Albertazzi R. Salvioni et al. High-dose chemotherapy supported with autologous bone marrow transplantation (ABMT) in germ-cell tumors: A phase two study Ann Oncol 3 10 1992 809-812
36. C.R. Nichols J. Andersen H.M. Lazrus et al. High-dose carboplatin and etoposide with autologous bone marrow transplantation in refractory germ cell cancer: An Eastern Co-operative Oncology Group protocol J Clin Oncol 10 4 1992 558-563
37. W. Siegert J. Beyer I. Strohscheer et al. High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: A phase I/II study. The German Testicular Cancer Co-operative Study Group J Clin Oncol 12 6 1994 1223-1231
38. A. Flechon P. Biron J.P. Droz High-dose chemotherapy with hematopoietic stem-cell support in germ-cell tumor patient treatment: The French experience Int J Cancer 83 6 1999 844-847
39. A. Kellner C. Grothey H. Rie J. Schmoll Sequential high-dose chemotherapy with paclitaxel, ifosfamide, carboplatin and etoposide (HD P-ICE) for platinum refractory and multiple relapsed germ cell cancer (GCC). Results of a phase II study Proc Am Cancer Soc 1774 2003 442
40. A. Ibrahim E. Zambon J.H. Bourhis et al. High-dose chemotherapy with etoposide, cyclophosphamide and escalating dose of carboplatin followed by autologous bone marrow transplantation in cancer patients: A pilot study Eur J Cancer 29A 10 1993 1398-1403
41. R.J. Motzer M. Mazumdar G.J. Bosl et al. High-dose carboplatin, etoposide, and cyclophosphamide for patients with refractory germ-cell tumors: Treatment results and prognostic factors for survival and toxicity J Clin Oncol 14 4 1996 1098-1105
42. M.J. Barnett C.M. Coppin N. Murray et al. High-dose chemotherapy and autologous bone marrow transplantation for patients with poor prognosis nonseminomatous germ-cell tumours Br J Cancer 68 3 1993 594-598
43. B.K. Margolin J.H. Doroshow C. Ahn et al. Treatment of germ cell cancer with two cycles of high-dose ifosfamide, carboplatin, and etoposide with autologous stem-cell support J Clin Oncol 14 10 1996 2631-2637
44. E.R. Broun C.R. Nichols G. Gize et al. Tandom high dose chemotherapy with autologous bone marrow transplantation for initial relapse of testicular germ cell cancer Cancer 79 8 1997 1605-1610
45. S. Bhatia R. Abonour P. Porcu et al. High-dose chemotherapy as initial salvage chemotherapy in patients with relapsed testicular cancer J Clin Oncol 18 19 2000 3346-3351
46. O. Rick C. Bokemeyer J. Beyer et al. Salvage treatment with paclitaxel, ifosfamide, and cisplatin plus high-dose carboplatin, etoposide, and thiotepa followed by autologous stem-cell rescue in patients with relapsed or refractory germ cell cancer J Clin Oncol 19 1 2001 81-88
47. G. Rosti J.-L. Pico H. Wandt et al. High-dose chemotherapy (hdc) in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours (GCT); first results of a prospective randomised trial of the European Group for Blood and Marrow Transplantation (EBMT): IT-94 Proc Ann Meet Am Soc Clin Oncol 716 2002
48. J. Beyer High dose versus conventional dose first salvage treatment in nonseminoma;a matched pair analysis Proc Ann Meet Am Soc Clin Oncol 1255 1999
49. J. Beyer A. Kramar R. Mandanas et al. High-dose chemotherapy as salvage treatment in germ-cell tumors: A multivariate analysis of prognostic variables J Clin Oncol 14 10 1996 2638-2645
50. J.P. Droz J.L. Pico M. Ghosn et al. A phase II trial of early intensive chemotherapy with autologous bone marrow transplantation in the treatment of poor prognosis non-seminomatous germ-cell tumors Bull Du Cancer 79 5 1992 497-507
51. C. Chevreau J.P. Droz J.L. Pico et al. Early intensified chemotherapy with autologous bone marrow transplantation in first-line treatment of poor-risk of non-seminomatous germ-cell tumours Preliminary results of a French randomised trial Eur Urol 23 1 1993 213-217
52. R.J. Motzer M. Mazumdar S.C. Gulati et al. Phase II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ-cell tumors J Natl Cancer Inst 85 22 1993 1828-1835
53. M.J. Morris G.J. Bosl High dose chemotherapy as primary treatment for poor-risk germ-cell tumors: The Memorial Sloan-Kettering Experience (1988-1999) Int J Cancer 83 6 1999 834-838
54. H.J. Schmoll C. Kollmannsberger B. Metzner et al. Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: An extended phase I/II study of the German Testicular Cancer Study Group J Clin Oncol 21 22 2003 4083-4091